Compositions containing thrombin and microfibrillar collagen and methods for preparation and use thereof

• US 6,280,727 B1
• Filed: 11/09/1999
• Issued: 08/28/2001
• Est. Priority Date: 06/18/1997
• Status: Expired due to Term

• Current Assignee: Surgical Specialties Corporation Limited (Ssc Holdco Ltd)
• Original Assignee: Cohesion Technologies Inc. (Angiotech Pharmaceuticals Incorporated)
• Inventors: Prior, Jeffrey J., Sierra, David H., Wallace, Donald G., DeLustro, Frank A.
• Primary Examiner(s): Wortman, Donna C.
• Assistant Examiner(s): Zeman, Robert A.
• Application Number:
  US09/436,903
• Time in Patent Office: 658 Days
• Field of Search: 435/13, 435/18, 514/2, 514/21, 530/356, 530/380, 530/381, 530/382, 424/94.1, 424/94.63
• US Class Current: 424/94.63
• CPC Class Codes: A61L 24/043 Mixtures of macromolecular materials
• CPC Class Codes: A61L 24/102 Collagen
• CPC Class Codes: A61L 24/106 Fibrin; Fibrinogen
• CPC Class Codes: A61L 2400/04 Materials for stopping bleeding
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: C08L 89/06 derived from leather or skin , e.g. gelatin

Abstract

The present invention relates to thrombin-containing hemostatic compositions, their preparation and use. In particular, it relates to hemostatic compositions comprising stabilized thrombin and microfibrillar collagen in an aqueous medium. In a preferred embodiment of the present invention, the compositions are used in a kit comprising two different components, one of which is autologous patient'"'"'s plasma as the source of fibrinogen, and the other of which is the thrombin-containing composition which also contains microfibrillar collagen.

Claims

1. A hemostatic composition comprising thrombin and microfibrillar collagen in an aqueous medium, wherein the microfibrillar collagen has an average diameter of about 3-30 nm.

2. The composition of claim 1, wherein the thrombin is bovine thrombin.

3. The composition of claim 1, wherein the thrombin is recombinant thrombin.

4. The composition of claim 1, wherein the thrombin is a thrombin-like compound.

5. The composition of claim 1, wherein the microfibrillar collagen has a melting temperature of about 42 to 46°

C.

6. The composition of claim 1 further comprising calcium ions.

7. The composition of claim 6, wherein the calcium ions are present in the form of calcium chloride.

8. The composition of claim 6, wherein the calcium ions are present at a concentration which is effective to disassemble fibrillar collagen into microfibrillar collagen.

9. The composition of claim 1, wherein the thrombin retains 80% or more of its activity after storage at 2-8°

C. for at least 6 months.

10. The composition of claim 1 further comprising polyethylene glycol.

11. The composition of claim 10, wherein the polyethylene glycol has an average molecular weight of about 1,000 to 8,000.

12. The composition of claim 10, wherein the polyethylene glycol is present at a concentration of between 0.1% and 2% w/v.

13. The composition of claim 12, wherein the polyethylene glycol is present at a concentration of between 0.1 and 0.3% w/v.

14. The composition of claim 1, wherein the pH of the composition is between 4.5 and 6.6.

15. The composition of claim 1, wherein the pH of the composition is between 5.0 and 5.7.

16. The composition of claim 1 further comprising at least one sugar, wherein the sugar is present in an amount which is effective to stabilize the thrombin.

17. The composition of claim 1, wherein the sugar is selected from the group consisting of:

mannitol, sorbitol, glucose and sucrose.

18. The composition of claim 1 further comprising at least one biologically active agent.

19. The composition of claim 18, wherein the biologically active agent is selected from the group consisting of:

growth factors, antibiotics and therapeutic agents.

20. The composition of claim 1, further comprising fibrinogen.

21. The composition of claim 1, further comprising at least one thrombin stabilizer.

22. The composition of claim 21, wherein the thrombin stabilizer is selected from the group consisting of:

sugar, a thrombin inhibitor, a calcium chelator and a protein.

23. The composition of claim 1, wherein the composition is flowable through an opening of about 200 to 1000 microns.

24. A kit comprising the composition of claim 1 and a source of fibrinogen.

25. The kit of claim 24, wherein the source of fibrinogen is fibrinogen in an aqueous medium.

26. The kit of claim 24, wherein the source of fibrinogen is plasma.

27. The kit of claim 26, wherein the plasma is human plasma.

28. The kit of claim 27, wherein the plasma is autologous plasma.

29. A kit comprising the composition of claim 1 and a suspension of platelets.

30. The composition of claim 1, wherein the microfibrillar and non-microfibrillar collagen are present in the composition at a ratio of at least 1:

1 (w/w), respectively.

31. The composition of claim 1, wherein the microfibrillar collagen has a fibril length of about 400 to 500 nm.

32. A method for promoting hemostasis of a tissue site on or in a body of a mammalian subject comprising the steps of:

(a) providing a hemostatic composition comprising thrombin and microfibrillar collagen in an aqueous medium, wherein the microfibrillar collagen has an average diameter of about 3-30 mn;

(b) providing an aqueous medium comprising fibrinogen;

(c) mixing the hemostatic composition and the aqueous medium comprising fibrinogen immediately prior to contact with the tissue site; and

(d) contacting the mixture with the tissue site.

33. The method of claim 32, wherein the aqueous medium comprising fibrinogen is plasma, and the step of providing an aqueous medium comprising fibrinogen further comprises isolating the plasma from the mammalian subject.

34. The method of claim 32, wherein the mammalian subject is a human and the plasma is human plasma.

35. The method of claim 33, wherein the human plasma is isolated from a sample of blood from the human subject.

36. The method of claim 32, wherein the step of mixing takes place in an apparatus during delivery of the hemostatic composition and the aqueous medium comprising fibrinogen to the tissue site.

37. The method of claim 32, wherein the step of mixing takes place after the hemostatic composition and the aqueous medium comprising fibrinogen exit the apparatus, but before the hemostatic composition and the aqueous medium comprising fibrinogen contact the tissue site.

38. A method for promoting hemostasis of a tissue site on or in a body of a mammalian subject comprising the steps of:

(a) providing a hemostatic composition comprising thrombin and microfibrillar collagen in an aqueous medium, wherein the microfibrillar collagen has an average diameter of about 3-30 nm;

(b) providing an aqueous medium comprising platelets;

(c) mixing the hemostatic composition and the aqueous medium comprising platelets immediately prior to contact with the tissue site; and

(d) contacting the mixture with the tissue site.

39. A method of making a composition for use as a hemostatic agent comprising the steps of:

(a) mixing thrombin, fibrillar collagen and a fiber disassembly agent together in an aqueous medium, wherein the fiber disassembly agent is present at a concentration which is effective at disassembling the fibrillar collagen into microfibrillar collagen; and

(b) incubating the mixture formed in step (a) for a sufficient length of time and at a sufficient temperature to form microfibrillar collagen having a stable fiber size wherein the stable fiber size is about 3-30 nm in average diameter.

40. The method of claim 39, wherein the fiber disassembly agent is calcium ions.

41. The method of claim 40, wherein the calcium ions are present at a concentration of between 10 and 200 mM.

42. The method of claim 41, wherein the method further comprises adding fibrinogen to the aqueous medium.